Latest Breaking News On - Cyril amarchand mangladas - Page 1 : comparemela.com

Roivant Purchases Silicon Therapeutics Roivant Sciences has agreed to acquire  Silicon Therapeutics for $450 million in Roivant equity, with additional potential regulatory and commercial milestone payments. The acquisition of Silicon Therapeutics bolsters Roivant’s targeted protein degradation platform. That platform will be powered by VantAI’s advanced machine learning models trained on proprietary degrader-specific experimental data and by Silicon Therapeutics’ proprietary computational physics capabilities, which help address many of the modality-specific challenges of degrader design and optimization. Integrating Silicon Therapeutics and VantAI will enable Roivant to distinctively capture the power of both computational physics and machine learning-based approaches to drug design; for instance, by incorporating proprietary computational physics simulations as training data for VantAI’s degrader-specific deep learning models.

Sumant sinhaCyril amarchand mangladasBob manciniMorgan stanley india company privateLatham watkinsAcquisition corporationNishith desai associatesPower privateGoldman sachs india securities privateMorgan stanley coEnergy globalRenew power private limitedNasdaq capitalRenew energy globalSecurities private limitedMorgan stanley india company private limited